Introduction to Clinical Benefit-Risk Assessment for the evaluation of (new) medicinal products

Pieter Neels, MD
Independent Regulatory Expert
Chair of the Human Vaccine Committee of IABS

Ex- CHMP member for Belgium
Ex- Vice-chair VWP (EMA)
Disclaimer

• Although I have been a member of the CHMP, my presentation might not represent the views of the CHMP, the European Medicines Agency (EMA), the Belgian Medicines Commission, neither of the Vaccine Working Party.

• My presentation is a personal viewpoint and binds in no way the organisations mentioned before.
Declaration of interest

I have signed consultancy contracts with more than 100 organisations and companies under which

- WHO
- B&MGF
- Universities of Antwerp, Ghent, Leuven, Namur, Brussels, Paris, Lausanne, Köln, ...
- Big pharma
- Medium pharma
- Small pharma
Part 1: Context and Historical Background Information
Context and Background Information (1)

- Regulation of medicinal products for human use has been developed in the past century.
- In the past, many regulatory decisions to license a new product have been based only on available data from clinical trials.
- However, lessons learnt from public health incidents over the post-licensure period showed that clinical data is often limited at the time of licensure and therefore commitments to monitoring of rare serious adverse events in the post-marketing period, in large populations, became a requirement for licensure.
- Such monitoring programmes focused mostly on safety.
Example 1 Smallpox

Would the smallpox vaccine be licensed in 2022 knowing the AE data today:

Historically, for every 1 million primary vaccine recipients, there would be approximately 5 to 10 persons with adverse reactions serious enough to require hospitalization and 1 or two deaths. In the absence of smallpox (or other poxvirus) exposure, these risks are unnecessary. However, they pale in comparison with those encountered during a smallpox epidemic. In fact, a smallpox outbreak with 1 million cases among an unvaccinated population would result in hundreds of thousands of deaths and long-term sequelae (blindness, limb deformities, facial scarring, and depigmentation) among the majority of the survivors.

⇒ Thus in a scientific B/R analysis we look at the prevention of more than 100,000 deaths per million compared to 1-2 deaths due to vaccination.
⇒ B/R is still highly positive, however knowing the COVID-19 pandemic polemic on vaccine safety, which politician would take this decision today?
Example 2 RotaShield

- Rotashield was licensed in the US 08/1998, after commercialising a link with intussusception was found:

Intussusception from all other causes is most common among infants in the first year of life; 1 child in 2,000 children to 1 child in 3,000 children is affected before one year of age. Based on the results of the investigations, CDC estimated that 1 or 2 additional cases of intussusception would be caused among each 10,000 infants vaccinated with RotaShield® vaccine.

https://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm

⇒ Thus in a scientific B/R analysis we look at the prevention of a treatable disease (diarrhea), while the vaccination could give a SAE, potentially life-threatening.

⇒ B/R in HIC’s was evaluated as negative,… however in LMIC’s where the disease might be related to a high mortality the B/R might be positive

⇒ Is it possible to license a vaccine in a LMIC, when the HIC’s have refused the vaccine?
Context and Background Information (2)

Confronted with the complexity of registration dossiers, regulators have been “realistic” and have relied on “value” judgments.

The basis and process of the regulatory decisions are mostly implicit.

There was no agreed approach on the methodology for B/R assessment until the publication of ICH E2C*, in 1996. Prior to that, much was based on “gut feeling”.

* https://www.ich.org/page/efficacy-guidelines
Context and Background Information (3)

Western societies have shifted towards a **risk-averse attitude**, based on the idea that vaccines should provide a **personal health benefit** to the vaccinee rather than a **benefit for the community or population** at risk of infectious diseases, conferred by heard immunity, which is the notion that vaccines may have global clinical benefits that are more valuable than individual adverse events.

Example of COVID-19 vaccination of all people:

while young age groups are less prone to complications of severe acute respiratory syndrome (COVID-19) caused by the SARS-Cov2 virus, creating an aversion to vaccination, vaccination of all age groups can help protection for vulnerable groups (e.g. elderly age groups) against disease/hospitalization?
In part, this “objectivation of value judgement” (but not all) is linked to the increased concern about risk (cf. highly media publicised drug withdrawals)

Does it reflects risk aversion or risk awareness?

The society has shifted towards the individual health concern:
• My child should be vaccinated with a vaccine without any AE.
• What is my benefit, if I get a vaccine, and not what is the benefit for the population...
B/R Balance concept

The concept is dynamic:

- The first exercise is done at licensure, however every PSUR will have a new B/R analysis
- Whenever a new safety issue is discovered, a new B/R analysis has to be carried out

Example: Both vector vaccines of J&J and AZ, were re-analysed when thrombosis cases were linked to the vaccination.
Collaboration between WHO GACVS and the Brighton Collaboration led to acceptance by GACVS of the B/R templates offered by Brighton:

New templates developed focusing on key questions related to the essential safety and benefit risk assessment of vaccine technologies for the main COVID-19 platforms (funded by CEPI)

• Nucleic Acid (RNA) vaccines Kim D et al, [https://doi.org/10.1016/j.vaccine.2020.06.017](https://doi.org/10.1016/j.vaccine.2020.06.017)
• Protein vaccines Kochhar S et al, [https://doi.org/10.1016/j.vaccine.2020.06.044](https://doi.org/10.1016/j.vaccine.2020.06.044)
• Viral vector vaccines Condit RS et al, [https://doi.org/10.1016/j.vaccine.2020.08.009](https://doi.org/10.1016/j.vaccine.2020.08.009)
• Live attenuated viral vaccines Gurwith M et al, [https://doi.org/10.1016/j.vaccine.2020.09.042](https://doi.org/10.1016/j.vaccine.2020.09.042)
New paradigm for vaccine development and licensure

- The pandemic COVID-19 vaccine development in 2020 demonstrated that new, safe and efficacious vaccines can be developed and tested within less than 12 months. Cfr. https://www.nature.com/articles/d41586-020-03626-1
- The question arises: is this fast enough for a potential future pandemic with higher pathogenicity and higher mortality rates than COVID-19?
- Therefore, the new approach for vaccine regulatory approval includes now also formal benefit-risk assessment, in addition to quality, safety, and efficacy evidence.
- CEPI has come with the “100 days” from development to license idea
The regulatory paradox

• The above background and examples illustrate the regulatory paradox that, while regulatory authorities require thorough testing procedures, increasing amount of data and larger clinical studies, that may take a long time and high resources, and at the same time, health authorities need to have new efficacious medicinal products to be rapidly available to fight the spread of infectious diseases as soon as possible, to save lives in epidemic and pandemic situations.

• Protection of the user/patient are based on learnings from:
  o Incidents from the past
  o Guidance on public health criteria for
    ➢ Quality
    ➢ Efficacy
    ➢ Safety
    ➢ Risk Management
  o Declaration of Helsinki: ethical regulation of Clinical Trials

• Promotion of the availability of indispensable medicines
Two major examples of the regulatory paradox

1) Elixir Sulfanilamide case

   - Diethyleen Glycol (DEG), organic solvent

   - Used in a solution of sulfanilamide → Elixir Sulfanilamide, cause of 107 deaths in US in 1938

   - Reason to implement the FDA Federal Food, Drug and Cosmetic Act (1938)
The regulatory paradox: example

2) Thalidomide

- Between 1956 and 1961 thalidomide was used in ± 50 countries, sold under at least 40 different brand names
- Indication: nausea and insomnia in early pregnancy
- Between 1957 and 1962: ± 10,000 children were born with phocomelia, or limbs’ malformation
- Impact in the US was limited, as the FDA did not approve the use of thalidomide due to limited safety data
To address concerns about risks of new drugs and other medicinal products including vaccines, regulatory agencies established more and better regulatory requirements, including systematic review of safety data, at pre- and post-marketing periods.

Therefore, several organizations created various working groups and guidelines, see next slide:
**History (2)**

1992: CIOMS\(^1\) created the working group II on:
- “Regular, systematic review of global safety data available to the MAH” or “International reporting of Periodic Drug-Safety Update Summaries”? (comment by Katharina Hartmann)


1996: ICH\(^3\) Guideline E2C, on Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
- intended to harmonise the periodic reporting requirements to regulatory authorities and to provide, in a common format, the worldwide interval safety experience of a medicinal product at defined times post-approval

But all this appeared not to be efficient enough to obtain the data on safety of medicinal products

---

(1) Council for International Organizations of Medical Sciences, [www.cioms.ch](http://www.cioms.ch)
(3) International Harmonization Council, [www.ich.org](http://www.ich.org)
Further new initiatives were triggered by several incidents

E.g.: in 1996 Fen-Phen obesity treatment led to heart valvulopathy and pulmonary hypertension with significant fatalities \(^{(2)}\)


Indeed, medicinal products are now evaluated also as to their benefits and their risks at registration, and on related adverse reactions data collection, that must be compared to their incidence/frequency in the untreated population. Based on such baseline data the clinical benefits can be weighted against observed risks.

Sources and guidance

ICH

• PERIODIC BENEFIT-RISK EVALUATION REPORT (PBRER) E2C(R2)
  • http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effica
cy/E2C/E2C_R2_Step4.pdf
Thus it seems necessary to clarify the PSUR or PBRER in the same context:

- What is the relevance of an Adverse Drug Event?
- What is the Observed versus Expected equation/ratio as compared to the naïve/untreated population?
  - Do we know the incidence of a given disease (e.g. intussusception...) in the naïve population?
- Is there an increased incidence of any adverse events in a vaccinated population?
- Is there a direct link of (temporal) causality?
- Weighting the benefits against the observed risk...
However, on the other hand, successful vaccination contributes to elimination and eradication of infectious diseases, hence decreasing peoples’ willingness to be vaccinated, as they don’t see disease anymore, particularly in some countries with high vaccination coverages.

This may lead to difficulties in keeping population vaccination rates at high levels, such as Yellow Fever in Brazil (example of reemergence of YF outbreaks in 2017-18 See next slide)

- What is the benefit of a vaccination for a population against a disease that has disappeared or almost disappeared such as poliomyelitis, HiB, tetanus, Hepatitis B in the US or in the EU and other countries?
  - If there is an increase of incidence of Adverse Events after immunization, is the vaccine the real causality?
  - Weightening the benefits against the observed risk...
Yellow fever virus outbreaks: case study

Yellow fever virus originated in Africa and was brought to the western hemisphere during the slave trade era, with the first epidemic reported in 1648 in the Yucatan. Over the years, outbreaks occurred widely in tropical America, the North American coastal cities, and Europe. It was recognized that yellow fever was not communicable person-to-person, and in 1881, Carlos Finlay of Cuba significantly advanced the field when he suggested Culex cubensis (now known as Aedes aegypti) as the mosquito responsible for spreading the disease. Walter Reed went to Cuba to investigate the cause of yellow fever. Reed's work proved that Aedes aegypti mosquitoes were the primary mode of transmission for the disease and that yellow fever was caused by a filterable agent found in the blood of infected patients. Cf. Yellow Fever: 100 Years of Discovery. JAMA doi:10.1001/jama.300.8.960

Yellow fever is an acute viral haemorrhagic disease of typically short duration. In most cases, symptoms include fever, chills, loss of appetite, nausea, muscle pains and headaches. In about 15% of people, abdominal pain occurs, and liver damage begins causing yellow skin, with the risk of bleeding and kidney problems. The virus is endemic in tropical areas of Africa and Central and South America. The virus is an RNA virus of the genus Flavivirus. Cf. Fields Virology (5th ed.). Philadelphia, PA: Lippincott Williams & Wilkins. p. 1101. ISBN 978-0-7817-6060-7.

Yellow fever is prevented by an extremely effective vaccine, which is safe and affordable. A single dose of yellow fever vaccine is sufficient to grant sustained immunity and life-long protection against yellow fever disease. Cf. https://www.who.int/news-room/fact-sheets/detail/yellow-fever
Yellow fever virus outbreaks: case study background

In 2017–2018, cities in south-eastern Brazil experienced an unusual outbreak of yellow fever virus, where no urban cases were reported. In the early 20th century, these cities had large outbreaks of yellow fever, spread by Aedes mosquitoes, but they had been free of yellow fever since 1942, nearly a century. The re-emergence of yellow fever in densely populated urban areas raises serious concerns about re-establishing ongoing transmission in cities, spread by urban Aedes mosquitoes.

On 25 January 2019, PAHO/WHO alerted Member States about the beginning of the seasonal period for yellow fever and therefore, the highest risk of transmission to unvaccinated subjects. Thus, PAHO/WHO advises Member States with areas at-risk for yellow fever to continue efforts to immunize susceptible populations and to take the necessary actions to keep travellers informed and vaccinated prior to traveling to areas at risk of yellow fever.
Reemergence of yellow fever virus in southeastern Brazil, 2017–2018: What sparked the spread?

Cf. https://doi.org/10.1371/journal.pntd.0010133

Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation Cf. https://www.scielo.br/j/mioc/a/3YkjX4xbMb88BxVy6qCNsgf/?lang=en#
1. **INTRODUCTION**

The Periodic Benefit-Risk Evaluation Report (PBRER) described in this Guideline is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the ICH regions.

This Guideline defines the recommended format and content of a PBRER and provides an outline of points to be considered in its preparation and submission.

Definitions of many technical terms used in the Guideline are included in a glossary (Appendix A); the first mention of a term in the Guideline is identified with an asterisk (*).
Sources

ICH
- PERIODIC BENEFIT-RISK EVALUATION REPORT (PBRER) E2C(R2)

EMA
- Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases
- Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report
- Guidance document on the content of the <Co-> Rapporteur day 80 critical assessment report
Sources

Part 2: Discussion on Benefit-Risk balance assessment and a few examples
**Definition of Benefit/Risk (B/R):**
Benefit/Risk assessment for medicinal products is a complex area requiring solid scientific knowledge and expertise

**Benefit:** proven therapeutic good  
**Risk:** probability of harm being caused

Benefit & Risk are evaluative terms  
(contain value judgments)

⇒ B/R *balance* is more accurate than ratio

B/R assessment is a complex dynamic analysis rather than only a mathematical formula
Definition of Benefit/Risk (B/R)

How to define a Benefit for vaccines?

Ideally:

- Infection prevention goal:
  is the most desired goal for public health, so that vaccinated people don’t spread the disease. But infection prevention is a more difficult endpoint to achieve.

However, real world experience accepts clinical benefits of vaccination, such as:

- Disease prevention goal:
  vaccinated people don’t get the disease, but still get infected and can carry and spread the disease agent.

- Complication prevention goal:
  a percentage of vaccinenees get clinical disease, but **mild** such as measured by no hospitalisation, no intensive care needs, no mortality from the disease.
Definition of Benefit/Risk (B/R): Examples

1. Example Poliomyelitis vaccines:
   - OPV (attenuated oral polio vaccines): elicits local mucosal immunity and prevents further spread of infections
   - IPV (Inactivated Polio Vaccine): elicits disease prevention (no clinical myelitis), but elicits poor mucosal immunity, causing shedding of viruses in the environment, and the possibility to spread the virus.

2. Example COVID-19 vaccines:
   All known COVID-19 vaccines elicit certain degree of disease prevention (e.g. no clinical or mild clinical disease), but still enables carriage and shedding of viruses in the environment, and the possibility to spread the virus to vulnerable individuals.
Definition of Benefit/Risk (B/R): role of surrogates and correlates of protection

Because of the time lag period between infection and the manifestation of clinical disease for some pathogens, such as:

- Hepatitis B-virus, HPV, HIV,

it is extremely important to identify reliable surrogate endpoints for vaccine efficacy, as well as correlates of protection that allow to accelerate vaccine clinical development, licensure and availability to fight disease and save lives, without much delays.

Correlate of protection for Hepatitis B vaccines corresponds to sera antibody titters of 10 IU (International Units) per L? that confers life long protection. Demonstration that HepB vaccines elicit such level of titers in over 95% of naïve subjects allows licensure and protection to populations. (= Sero conversion rate)

However, for HIV candidate vaccines, the presence of antibodies is not correlated to any protection, unfortunately.
Definition of Benefit/Risk (B/R)

How to define a Benefit for vaccines?

• How to measure the effect of vaccines on disease, or how to translate disease prevention in a measurable clinical parameter:

In clinical trials, a surrogate endpoint (or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint, but does not necessarily have a guaranteed relationship. The National Institutes of Health (USA) defines surrogate endpoint as “a biomarker intended to substitute for a clinical endpoint”

Correlates of immunity/protection to a virus or other infectious pathogen are measurable signs that a person (or other potential host) is immune, in the sense of being protected against becoming infected and/or developing disease.

For many viruses, antibodies and especially neutralizing antibodies serve as a correlate of immunity. So for example, pregnant women are routinely screened in the UK for rubella antibodies to confirm their immunity to this infection which can cause serious congenital abnormalities. In contrast for HIV, the simple presence of antibodies is clearly not a correlate of immunity/protection since infected individuals develop antibodies without being protected against disease.
How to define a Benefit for vaccines?

- How to measure the effect of vaccines on disease, or how to translate disease prevention in a measurable clinical parameter?
  - **Hepatitis B virus** (1) can cause hepatocarcinoma, and due to vaccination the HepB endemicity has decreased: disease prevention is not an option as outcome for a clinical trial, hence
    - Surrogate of protection: Ab concentration (though no Cell Mediated Immune-parameter)
    - For Hep B it is established that a concentration above 10 IU/L confers lifelong protection
  - **Influenza**: Influenza like Illness (ILI PCR proven) is the standard: no Ab standard is available for the time being
  - **Haemophilus Influenzae**:
    - 2 cut-off 1,0 and 0,1

How to define a Benefit for vaccines?


1. Describe B&R in the specific therapeutic context
2. Describe amount, reliability and accuracy of available evidence
3. Be explicit about the perspectives of the various stakeholders, in particular patients and treating physicians
4. State the benefits in a way comparable with the risks – avoid relative expressions of B&R. Define the level of risk acceptability corresponding to the perceived degree of clinical benefit (in the specific context).
5. Describe how the B/R balance may vary across different factors (ex. patient characteristics)
6. Discuss the sensitivity of the B/R balance assessment to different assumptions (ex. “worst case scenario”)

Graphic illustration of Decision tree elements for Benefit-Risk Assessment

GREEN = benefit elements
RED = risk elements

- Treatment effect in pivotal trials
  - magnitude of effect for primary endpoints
  - statistical/design robustness
  - discontinuation rate due to lack of efficacy

- Benefit
  - anticipated patient compliance
  - confirmation of effect by secondary endpoints and non-pivotal trials

- Risk
  - interactions with other drugs and food
  - safety in subgroups
  - adverse effects in postmarketing surveillance
    - overall incidence
    - serious adverse effects
    - discontinuation rate due to adverse effects
      - preclinical signal
        - target organ
        - risk related to abnormal use
          - misuse
          - off-label use
          - abuse

- Clinical relevance of treatment effect
  - relevance of endpoints
  - relevance of studied population
  - relevance in subgroups
  - relevance of comparators
Elements for Benefit-Risk assessment

This task is extremely difficult and involves:

1. Uncertainty (re: probability of desirable and undesirable effects, effect size...)
2. Heterogeneity of effects across patient populations
3. Multiple objectives (maximising benefits & minimising risks)
4. Trading off effects of differential importance
5. Differences in perspectives (patient, societal, regulatory), ill-defined preferences and utilities of outcomes
6. Lack of agreement on what criteria to use
Elements for Benefit-Risk assessment

Excerpts from the CHMP B/R Assessment Template (BRA) (1)

Definition of a benefit = favourable (clinical) effect

• **Any beneficial effect** for the target population (often referred to as “benefit” or “clinical benefit”) that is associated with the product. These commonly include improvements in clinical efficacy but are not limited to efficacy (for example, a reduction in toxicity could also be a favourable effect).

• Describe the beneficial effects themselves and the uncertainty in the knowledge about these beneficial effects
Excerpts from the CHMP BRA Template (2)

Definition of a risk = unfavourable effect

• This would include any detrimental effects (often referred to as “risks”, “harm”, “hazards” both known and unknown) that can be attributed to the product or that are otherwise of concern for their undesirable effect on patients' health, public health, or the environment.

• Unfavourable effects are not necessarily limited to safety endpoints. For example, unfavourable effects may also be loss of efficacy, vaccine failure, waning immunity, lower efficacy towards pathogen genetic variants on important efficacy endpoints or other undesirable effect.

• Describe the unfavourable effects themselves and the uncertainty in the knowledge about these unfavourable effects
Case Study: Benefit-Risk Assessment of HPV vaccines efficacy endpoints
Benefit-Risk Assessment

Treatment effect in pivotal trials

Benefit

Risk

For HPV vaccines:
  • Effect on Cancer?
  • Not Ethical
  • Too expensive
  • Too long
Benefit-Risk Assessment

For HPV vaccines:
- Effect on Cancer?
- CIN2+?

- Not Easy: interpretation bias
- Several readers necessary
- Frequency rather low
Benefit-Risk Assessment

Treatment effect in pivotal trials

Benefit

Risk

For HPV vaccines:
• Effect Cancer?
• CIN2+?
• N1

• Difficult to accept: clearance too high
Benefit-Risk Assessment

Treatment effect in pivotal trials

Benefit

Risk

For HPV vaccines:
- Effect on Cancer?
- CIN2+?
- CIN1
- Persistent infection 12 months definition
- Persistent infection 6 months definition

- Not easy for regulators to accept asymptomatic infection as clinical end-point, as it clears often in less than a year.
- It is far away from cancer development
- However: no infection, no CIN, no cancer!
- Regulatory paradox: how to accept such approaches?
Benefit-Risk Assessment

For HPV vaccines:
- Effect on cancer?
- CIN2+?
- CIN1
- Persistent infection 12 months definition
- Persistent infection 6 months definition
- Immunogenicity, serum Ab levels?

- No protective threshold defined
- Will serum Ab translate in mucosal protection in the uterus epithelium?
- Mechanism of action?
Benefit-Risk Assessment

Uncertainty in the knowledge about the beneficial effects
- Pooling of data?
- Persistence of protection?
- Need for a booster?
- Comparability of study population and real world
- Extrapolation from 18-25 to 9-15
  - Higher immunity, and sufficient to be protective 10 years later?
- Extrapolation from clinical trial to real life
Benefit-Risk Assessment

Uncertainties in the knowledge about the beneficial effects
• Today additional questions could be asked:
  o What is the role of adjuvanted vaccines?
  o Why is it used? E.g. Cervarix
  o Can the vaccine be used without it
  o Why has the licensed competitor no (novel) adjuvant (only Alu)
Benefit-Risk Assessment

**Benefit**
- Treatment effect in pivotal trials
  - magnitude of effect for primary endpoints
  - discontinuation rate due to lack of efficacy
  - statistical/design robustness

**Risk**
- Further questions on HPV vaccination:
  - Research was done on 18-25y
  - But protection target age is <13 y
  - Effect on older populations?
  - Relevance of vaccination of > 45

**Clinical relevance of treatment effect**
- relevance of endpoints
- relevance of studied population
- relevance in subgroups
Benefit-Risk Assessment

Treatment effect in pivotal trials
- magnitude of effect for primary endpoints
- discontinuation rate due to lack of efficacy

Benefit
- statistical/design robustness

Risk
- Clinical relevance of treatment effect
  - relevance of endpoints
  - relevance of studied population
  - relevance in subgroups
  - relevance of comparators

For HPV vaccines:
- Is a placebo controlled RCT still possible for the next generation HPV trials given there are 5 efficacious vaccines now available?
**Benefit-Risk Assessment**

**Benefit**
- Treatment effect in pivotal trials
  - Magnitude of effect for primary endpoints
  - Statistical/design robustness
  - Discontinuation rate due to lack of efficacy
- Clinical relevance of treatment effect
  - Relevance of endpoints
  - Relevance of studied population
  - Relevance in subgroups
- Anticipated patient compliance

**Risk**

**For HPV vaccines:**
- Research: 3x doses in ages 18-25 y
- But target was <13 y adolescent compliance?
- Recent 1+1 new schedule approved, as non-inferiority on immunogenicity
Benefit-Risk Assessment

Benefit
- Treatment effect in pivotal trials
  - magnitude of effect for primary endpoints
  - statistical/design robustness
  - discontinuation rate due to lack of efficacy
- Confirmation of effect
  - by secondary endpoints and non-pivotal trials
- anticipated patient compliance

Risk
- Adverse Events in clinical trials
  - overall incidence
  - serious adverse events
  - discontinuation rate due to adverse events

Clinical relevance of treatment effect
- relevance of endpoints
- relevance of studied population
- relevance in subgroups
- relevance of comparators
Benefit-Risk Assessment

**Benefit**
- Treatment effect in pivotal trials
  - magnitude of effect for primary endpoints
  - discontinuation rate due to lack of efficacy
  - statistical/design robustness
- Confirmation of effect by secondary endpoints and non-pivotal trials
- Clinical relevance of treatment effect
  - relevance of endpoints
  - relevance of studied population
  - relevance in subgroups
- Anticipated patient compliance

**Risk**
- Adverse Events in clinical trials
  - overall incidence
  - serious adverse events
  - discontinuation rate due to adverse events
- Adverse Events in postmarketing surveillance

**Vaccine Advice**
Benefit-Risk Assessment

For HPV vaccines:
All of a sudden:

**Tragic Natalie ‘not killed by cancer jab’**

By ANDREW PARKER
Published: 30 Sep 2009

TRAGIC schoolgirl Natalie Morton did NOT die as a result of a cancer jab, it was thought last night. Early tests on the 14-year-old showed she had "a serious underlying medical condition". Natalie died hours after being given a Cervarix injection as part of a school inoculation programme.

There was chaos last night as some health and schools chiefs suspended vaccinations while the batch used at her school in Coventry was tested.

**There ARE side-effects that we’re NOT being told about**

Published: 06 Oct 2009

MUMS are fighting back over the controversial cervical cancer jab being dished out to young Scots schoolgirls.
Benefit-Risk Assessment

**Benefit**
- Treatment effect in pivotal trials
  - magnitude of effect for primary endpoints
  - statistical/design robustness
  - discontinuation rate due to lack of efficacy
- Confirmation of effect by secondary endpoints and non-pivotal trials
- Clinical relevance of treatment effect
  - relevance of endpoints
  - relevance of studied population
  - relevance in subgroups
- Anticipated patient compliance

**Risk**
- Adverse Events in clinical trials
  - overall incidence
  - serious adverse events
  - discontinuation rate due to adverse events
  - relevance of comparators
  - target organ
- Adverse Events in postmarketing surveillance
  - preclinical signal
  - risk related to abnormal use
    - misuse
    - off-label use
    - abuse

To be compared to alternative treatments
B/R assessment: the HPV vaccine example

Balance Positive Elements:

- Importance of favourable effects (benefits)
  - Prevention of an aggressive cancer
  - Even with high screening program activity: some patients will die
  - Reduction of secondary burden: early cervical conisation due to CIN lesions may lead to complications in pregnancy
  - Ongoing screening, decrease of CIN2 & CIN3 lesions
  - Reduction of psychological burden of being diagnosed with a lesion
B/R assessment: the HPV vaccine example

Balance Negative Elements:

- Importance unfavourable effects (risks)
  - Local tolerance: not a big issue
  - SAE from the CT database: not a big issue
  - Effect on auto-immunity: might be of importance, but no data yet
  - Effect on pregnancy: no clear signal from the CT data set
B/R assessment: the HPV vaccine example

Balance:

- Importance of favourable and unfavourable effects
- Benefit-risk balance
  - In the absence of clear Serious Adverse Events (SAE)
  - With a high potential of efficacy
    - Prevention of infection
    - Prevention of CIN lesions
  - Knowing the uncertainties
    - Will efficacy be translated in effectiveness? prevention of cancer
    - Large scale use: what will be the occurrence of SAE?

→ Balance is felt to be positive
Conclusions

Benefit / Risk Balance:

- Often clinical trial data are derived from a homogeneous setting, thus regulatory agencies need reflections on certainties and uncertainties of how such data can be applied to large and heterogeneous populations.

- It is a continuous process

- Needs to be repeated when new data become available
  - Collecting new data on benefits
  - Collecting New data on risks
  => B/R evaluation is important even if the benefit is forgotten due to disappearance of the disease

- R/B remains a difficult exercise knowing that for many Adverse Events the causal relationship is unknown...
Thank you for your attention!

Questions